J Korean Ophthalmol Soc > Volume 60(7); 2019 > Article
Journal of the Korean Ophthalmological Society 2019;60(7):661-666.
DOI: https://doi.org/10.3341/jkos.2019.60.7.661    Published online July 15, 2019.
Use of Anti-vascular Endothelial Growth Factors for Diabetic Retnopathy: National Health Insurance Claims Data.
Songhee Cho, Sang Jin Shin, Jae Kyung Suh, Hajin Tchoe, Jangmi Yang, Min Joo Kang, Donghyun Jee
1Office of Economic Evaluation Research, National Evidence Based Health Care Collaborating Agency, Seoul, Korea.
2Department of Ophthalmology and Visual Science, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. doj087@mail.catholic.ac.kr
당뇨망막병증에서 항혈관내피성장인자의 국내 사용 현황: 국민건강보험공단 자료 분석
한국보건의료연구원 경제성평가연구팀1, 가톨릭대학교 의과대학 성빈센트병원 안과 및 시과학교실2
Correspondence:  Donghyun Jee,
Email: doj087@mail.catholic.ac.kr
Received: 3 May 2018   • Revised: 19 July 2018   • Accepted: 19 June 2019
To evaluate the current use of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with diabetic retinopathy. METHODS: We determined the current number of diabetic retinopathy patients and their medical expenditure using National Health Insurance Service claims data (2007-2016). We also analyzed the medical costs of patients with diabetic retinopathy who received anti-VEGF treatment, including ranibizumab and aflibercept. We then evaluated aspects of the use of anti-VEGF injections, such as frequency and intervals, in newly diagnosed diabetic retinopathy patients who received anti-VEGF treatment, along with their medical costs. RESULTS: The number of patients with diabetic retinopathy was 397,956 in 2009 and 721,310 in 2016, a 1.8-fold increase over 8 years. Of these, the number of patients undergoing anti-VEGF therapy was 4,283 in 2015 and 4,270 in 2016. Of the diabetic retinopathy patients in 2016, the total medical cost of those treated with anti-VEGF was 1.5 billion won, and the average medical cost per person was 3,531,064 won. CONCLUSIONS: Based on the National Health Insurance claims data, the use of ranibizumab and aflibercept is increasing. The results of this study suggest that diabetic retinopathy will become an important public health issue.
Key Words: Aflibercept;Anti-vascular endothelial growth factor;Diabetic retinopathy;Ranibizumab

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society. All rights reserved.

Developed in M2community

Close layer
prev next